Kronik Psikiyatrik Hastalıklarda Nörotransmitter Sistemleri
Özet
Bu metin, kronik psikiyatrik hastalıkların nörobiyolojisinde rol oynayan dopaminerjik, glutamaterjik, serotonerjik, GABAerjik, kolinerjik ve adrenerjik nörotransmitter sistemlerinin sentez, metabolizma, reseptör yapıları ve yolaklarını detaylı şekilde incelemektedir. Dopaminerjik sistemdeki bozukluklar şizofrenideki pozitif/negatif belirtiler, DEHB'deki yürütücü işlev eksiklikleri ve ödül mekanizması üzerinden bağımlılıkla ilişkilendirilirken; glutamaterjik sistemdeki NMDA reseptör hipofonksiyonunun şizofreni, majör depresyon ve otizm fizyopatolojisinde kritik rol oynadığı belirtilmektedir. Santral sinir sisteminin ana inhibitör mekanizması olan GABAerjik sistem ile yaygın projeksiyonlara sahip serotonerjik sistemdeki düzensizliklerin anksiyete, depresyon ve alkol bağımlılığına zemin hazırladığı bulgulanmıştır. Kolinerjik sistemdeki nöronal dejenerasyonun Alzheimer hastalığındaki bilişsel düşüşün temel nedenlerinden biri olduğu, adrenerjik sistemdeki locus coeruleus kaynaklı aşırı uyarılmanın ise anksiyete semptomları ile DEHB fizyopatolojisinde etkin olduğu gösterilerek tüm bu sistemlerin psikofarmakolojik tedavilerde temel hedef olduğu vurgulanmaktadır.
This text thoroughly examines the synthesis, metabolism, receptor structures, and pathways of dopaminergic, glutamatergic, serotonergic, GABAergic, cholinergic, and adrenergic neurotransmitter systems playing roles in the neurobiology of chronic psychiatric disorders. Disregulations in the dopaminergic system are associated with positive/negative symptoms in schizophrenia, executive function deficits in ADHD, and addiction via the reward mechanism, while NMDA receptor hypofunction within the glutamatergic system is indicated to play a critical role in the pathophysiology of schizophrenia, major depression, and autism. It is established that abnormalities in the GABAergic system, the primary inhibitory mechanism of the central nervous system, and the widely projecting serotonergic system pave the way for anxiety, depression, and alcohol dependence. It is emphasized that neuronal degeneration in the cholinergic system is a fundamental cause of cognitive decline in Alzheimer's disease, whereas hyperarousal originating from the locus coeruleus in the adrenergic system is active in anxiety symptoms and ADHD pathophysiology, rendering all these systems core targets in psychopharmacological treatments.
Referanslar
Sourkes TL. Chapter 54: the discovery of neurotransmitters, and applications to neurology. Handb Clin Neurol. 2010;95:869-83. doi: 10.1016/S0072-9752(08)02154-4.
Dale H. Transmission of Nervous Effects by Acetylcholine: Harvey Lecture, May 20, 1937. Bull N Y Acad Med. 1937 Jul;13(7):379-96.
Attwell D, Barbour B, Szatkowski M. Nonvesicular release of neurotransmitter. Neuron. 1993;11(3):401-7. doi: 10.1016/0896-6273(93)90145-h.
Schatzberg, A. F., Nemeroff, C. B. (2017). The American Psychiatric Association Publishing textbook of psychopharmacology (Fifth edition.)Arlington: American Psychiatric Association Publishing.
Stahl, S. M. (2013). (4th ed.). Cambridge: Cambridge University Press.
Gardner BR, Hall DA, Strange PG. Agonist action at D2(short) dopamine receptors determined in ligand binding and functional assays. J Neurochem. 1997;69(6):2589-98. doi: 10.1046/j.1471-4159.1997.69062589.x.
Baik JH. Dopamine signaling in reward-related behaviors. Front Neural Circuits. 2013;7:152. doi: 10.3389/fncir.2013.00152.
Kebabian JW. Multiple classes of dopamine receptors in mammalian central nervous system: the involvement of dopamine-sensitive adenylyl cyclase. Life Sci. 1978;23(5):479-83. doi: 10.1016/0024-3205(78)90157-1..
Sahu A, Tyeryar KR, Vongtau HO, et al. D5 dopamine receptors are required for dopaminergic activation of phospholipase C. Mol Pharmacol. 2009;75(3):447-53. doi: 10.1124/mol.108.053017.
Klein MO, Battagello DS, Cardoso AR, et al. Dopamine: Functions, Signaling, and Association with Neurological Diseases. Cell Mol Neurobiol. 2019;39(1):31-59. doi: 10.1007/s10571-018-0632-3.
Depue RA, Collins PF. Neurobiology of the structure of personality: dopamine, facilitation of incentive motivation, and extraversion. Behav Brain Sci. 1999; 22(3):491-517; discussion 518-69. doi: 10.1017/s0140525x99002046.
Mogenson GJ, Nielsen M. Neuropharmacological evidence to suggest that the nucleus accumbens and subpallidal region contribute to exploratory locomotion. Behav Neural Biol. 1984;42(1):52-60. doi: 10.1016/s0163-1047(84)90424-2.
Damsma G, Pfaus JG, Wenkstern D, et al. Sexual behavior increases dopamine transmission in the nucleus accumbens and striatum of male rats: comparison with novelty and locomotion. Behav Neurosci. 1992;106(1):181-91. doi: 10.1037//0735-7044.106.1.181.
Mogenson GJ, Wu M, Jones DL. Locomotor activity elicited by injections of picrotoxin into the ventral tegmental area is attenuated by injections of GABA into the globus pallidus. Brain Res. 1980 ;191(2):569-71. doi: 10.1016/0006-8993(80)91308-6.
Crowley WR. Neuroendocrine regulation of lactation and milk production. Compr Physiol. 2015;5(1):255-91. doi: 10.1002/cphy.c140029. PMID: 25589271.
Clemens S, Rye D, Hochman S. Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective. Neurology. 2006 11;67(1):125-30. doi: 10.1212/01.wnl.0000223316.53428.c9.
Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry. 2003;160(1):13-23. doi: 10.1176/appi.ajp.160.1.13..
Luedtke R.R, Rangel-Barajas C, Malik M, et al. Bitropic D3 Dopamine Receptor Selective Compounds as Potential Antipsychotics. Curr. Pharm. Des. 2015;21:3700–3724.
Castner SA, Williams GV, Goldman-Rakic PS. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science. 2000;287(5460):2020-2. doi:10.1126/science.287.5460.2020.
Natesan S, Reckless GE, Barlow KB, et al. The antipsychotic potential of l-stepholidine--a naturally occurring dopamine receptor D1 agonist and D2 antagonist. Psychopharmacology (Berl). 2009;199(2):275-89. doi: 10.1007/s00213-008-1172-1.
Gross G, Wicke K, Drescher KU. Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia. Naunyn Schmiedebergs Arch Pharmacol. 2013;386(2):155-66. doi: 10.1007/s00210-012-0806-3.
Castellanos FX, Tannock R. Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes. Nat Rev Neurosci. 2002;3(8):617-28. doi: 10.1038/nrn896.
Volkow ND, Fowler JS, Wang G-J et al.Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies. Eur Neuropsychopharmacol 2002; 12: 557-566.
Faraone SV, Perlis RH, Doyle AE et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57:1313–1323
Kenny PJ. Common cellular and molecular mechanisms in obesity and drug addiction. Nat Rev Neurosci 2011;12:638
Everitt BJ, Robbins TW. Drug Addiction: Updating Actions to Habits to Compulsions Ten Years On. Annu Rev Psychol . 2016;67: 23–50, doi: 10.1146/annurev-psych-122414-033457.
Henry DJ, Hu X-T, White FJ . Adaptations in the mesoaccumbens dopamine system resulting from repeated administration of dopamine D1 and D2 receptor-selective agonists: relevance to cocaine sensitization. Psychopharmacology 1998; 140:233–242
Reiner A, Levitz J. Glutamatergic Signaling in the Central Nervous System: Ionotropic and Metabotropic Receptors in Concert. Neuron. 2018;98(6):1080-1098. doi: 10.1016/j.neuron.2018.05.018.
Özdemir O, Güzel Özdemir P. Glutamat sistemi ve Şizofreni Psikiyatride Güncel Yaklaşımlar. 2016;8(4):394-405
Moriguchi S, Takamiya A, Noda Y,et al. Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies. Mol Psychiatry. 2019;24(7):952-964. doi: 10.1038/s41380-018-0252-9.
Popoli M, Yan Z, McEwen BS, Sanacora G. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci. 2011;13(1):22-37. doi: 10.1038/nrn3138.
Corriger A, Pickering G. Ketamine and depression: a narrative review. Drug Des Devel Ther. 2019;13:3051-3067. doi: 10.2147/DDDT.S221437.
Purcell AE, Jeon OH, Zimmerman AW,et al. Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology 2001; 57: 1618.1628.
Shinohe A, Hashimoto K, Nakamura K, et al. Increased serum levels of glutamate in adult patients with autism. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30: 1472-1477.
Fiş N, Merkem M. Nörotransmitter sistemlerinin gelişimi ve psikopatolojiye yansımaları. Klinik Psikofarmakoloji Bülteni 2009; 19:312-321
Algül A, Alpay MA, Semiz ÜB, Çetin M. Reseptörler. In Temel Psikofarmakoloji (Ed N Yüksel):66-71. Ankara, Türkiye Psikiyatri Derneği, 2010.
Dean B, Pavey G, Thomas D, Scarr E. Cortical serotonin7,1D and 1F receptors: effect of schizophrenia, suicide and antipychotic drug treatment. Schizophr Res 2006; 88:265-274.
Fountoulakis KN, Gazouli M, Kelsoe J, et al: G The pharmacodynamic properties of lurasidone and their role in its antide pressant efficacy in bipolar disorder. Eur G Neuropsychopharmacol 2015:25(3):335-342, 25596883
Sanchez C, Asin KE, Artigas F: Vortioxetine, S a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther 2015:145:43-57, 25016186
Pilowsky LS, Busatto GF, Taylor M,et al. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology (Berl). 1996;124(1-2):148-53. doi: 10.1007/BF02245615..
Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:1159- 1172.
Yocca FD. Novel anxiolytic agents: actions on specific subtypes of central 5-HT receptors. Prog Clin Biol Res. 1990;361:145-77..
Greenberg BD, Tolliver TJ, Huang SJ et al. Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am J Med Genet. 1999;88(1):83-7.
Miller JM, Hesselgrave N, Ogden RT et al.Positron emission tomography quantification of serotonin transporter in suicide attempters with major depressive disorder. Biol Psychiatry. 2013;74(4):287-95. doi: 10.1016/j.biopsych.2013.01.024.
Wiste AK, Arango V, Ellis SP, Mann JJ, Underwood MD. Norepinephrine and serotonin imbalance in the locus coeruleus in bipolar disorder. Bipolar Disord. 2008 May;10(3):349-59. doi: 10.1111/j.1399-5618.2007.00528.x. PMID: 18402623.
Cooper, JR, Bloom, FE, Roth, RH. 2003. The Bio chemical Basis of Neuropharmacology, 8th Edition. New York, Oxford Univer sity Press,
Kaplan, H, Saddock, B. (2015). Comprehensive Textbook of Psychiatry. 11th Ed. New York: Wolters Kluwer
Nestler EJ, Hyman SE, Holtzman DM, et al: 2015. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience, 3rd Edition. New York, McGraw-Hill.
Cameron OG, Huang GC, Nichols T, et al. Reduced γ-Aminobutyric AcidA–Benzodiazepine Binding Sites in Insular Cortex of Individuals With Panic Disorder. Arch Gen Psychiatry. 2007;64(7):793–800. doi:10.1001/archpsyc.64.7.793
Şendur İ, Kalkan Oğuzhanoğlu N, Sözeri Varma G. Study on Dorsolateral Prefrontal Cortex Neurochemical Metabolite Levels of Patients with Major Depression Using H-MRS Technique. Turk Psikiyatri Derg. 2020 (2):75-83. doi: 10.5080/u22978..
Shiah IS, Yatham LN (1998) GABA function in mood disorders: an update and critical reviews. Life Sci, 63:1289-1303.
Rosso IM, Weiner MR, Crowley DJ, et al.Insula and anterior cingulate GABA levels in posttraumatic stress disorder: preliminary findings using magnetic resonance spectroscopy. Depress Anxiety. 2014(2):115-23. doi: 10.1002/da.22155.
Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 1976; 2: 1403.
Whitehouse PJ, Price DL, Clark AW et al. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981; 10: 122–6.
Geula C, Mesulam M, Saroff D et al. Relationship between plaques, tangles, and loss of cortical cholinergic fibers in Alzheimer disease J Neuropath Exp Neurol 1998; 57: 63–75.
Foote SL, Bloom FE, Aston-Jones G: Nucleus God locus ceruleus: new evidence of anatom ical and physiological specificity. Phys iol Rev 63(3):844-914, 1983 6308694
Tejani-Butt SM, Brunswick DJ, Frazer A: [3H] Nisoxetine: a new radioligand for nor epinephrine uptake sites in brain. Eur J Pharmacol 191(2):239-243, 1990 2086242
Hohen-Saric R, Merchant AF, Keyser ML et al.Effects of clonidine on anxiety disorders. Arch Gen Psychiatry, 1981;38:1278- 1282
Reisine T. Adaptive changes in catecholamine receptors in the central nervous system. Neuroscience, 1981;6:1471-1502.
Redmond DE, Huang YH (1979) New evidence for a locus ceruleus-norepinephrine connection with anxiety. Life Sci, 25:2149-2162.
Holmberg G, Gershon S (1961) Autonomic and psychic effects of yohimbine hydrochloride. Psychopharmacologia, 2:93-106.
Hohen-Saric R, Merchant AF, Keyser ML ve ark. (1981) Effects of clonidine on anxiety disorders. Arch Gen Psychiatry, 38:1278- 1282.
Slattery DA, Hudson AL, Nutt DJ (2004) Invited review: The evolution of antidepressant mechanisms. Fundam Clin Pharmacol, 18:1-21
Castellanos F, Tannock R. Neuroscience of attention deficit hyperactivity disorder: the search for endophenotypes. Nat Rev Neurosci 2002; 3: 617-628.
Arnsten A, Steere JC, Hunt RD. The contribution of alpha sub 2- noradrenergic mechanisms to prefrontal cortical cognitive function: potential significance for attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1996; 54: 448-455
Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, et al. (2002): Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699 –711. 109.
Spencer T, B iederm an J, W ilens T ve ark. (1998) Effectiveness a nd tolerability o f tom oxetine in adults w ith attention deficit hyperactivity disorder. A m J Psychiatry 155(5): 693-5
